Literature DB >> 22122639

Epigenetic biomarker development.

Christoph Bock1.   

Abstract

Epigenetic mechanisms control gene expression in a way that is stably propagated over multiple cell divisions, but which is also flexible enough to respond to environmental influences. This intermediate position between stability and plasticity renders epigenetic information highly useful for monitoring cellular states in the context of personalized medicine. Epigenetic alterations have also been identified as causal events for common diseases such as cancer and autoimmune disorders. The goal of epigenetic biomarker development is to design experimental assays that produce relevant information for diagnosis, prognosis and therapy optimization in routine clinical treatment and drug discovery. Here, I outline a systematic approach to epigenetic biomarker development and highlight key bioinformatic tools that facilitate discovery, optimization and validation of novel biomarkers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 22122639     DOI: 10.2217/epi.09.6

Source DB:  PubMed          Journal:  Epigenomics        ISSN: 1750-192X            Impact factor:   4.778


  42 in total

Review 1.  Analysing and interpreting DNA methylation data.

Authors:  Christoph Bock
Journal:  Nat Rev Genet       Date:  2012-10       Impact factor: 53.242

2.  The development and validation of EpiComet-Chip, a modified high-throughput comet assay for the assessment of DNA methylation status.

Authors:  Todd A Townsend; Marcus C Parrish; Bevin P Engelward; Mugimane G Manjanatha
Journal:  Environ Mol Mutagen       Date:  2017-07-29       Impact factor: 3.216

3.  New DNA Methylation Markers for Pancreatic Cancer: Discovery, Tissue Validation, and Pilot Testing in Pancreatic Juice.

Authors:  John B Kisiel; Massimo Raimondo; William R Taylor; Tracy C Yab; Douglas W Mahoney; Zhifu Sun; Sumit Middha; Saurabh Baheti; Hongzhi Zou; Thomas C Smyrk; Lisa A Boardman; Gloria M Petersen; David A Ahlquist
Journal:  Clin Cancer Res       Date:  2015-05-28       Impact factor: 12.531

4.  Accurate Measurement of DNA Methylation: Challenges and Bias Correction.

Authors:  Eguzkine Ochoa; Verena Zuber; Leonardo Bottolo
Journal:  Methods Mol Biol       Date:  2022

Review 5.  Epigenetics advancing personalized nanomedicine in cancer therapy.

Authors:  Shujun Liu
Journal:  Adv Drug Deliv Rev       Date:  2012-08-19       Impact factor: 15.470

6.  MethMarker: user-friendly design and optimization of gene-specific DNA methylation assays.

Authors:  Peter Schüffler; Thomas Mikeska; Andreas Waha; Thomas Lengauer; Christoph Bock
Journal:  Genome Biol       Date:  2009-10-05       Impact factor: 13.583

7.  Biomarkers for Bone Tumors: Discovery from Genomics and Proteomics Studies and Their Challenges.

Authors:  Wan I Wan-Ibrahim; Vivek A Singh; Onn H Hashim; Puteri S Abdul-Rahman
Journal:  Mol Med       Date:  2015-11-13       Impact factor: 6.354

8.  Genome-scale DNA methylation mapping of clinical samples at single-nucleotide resolution.

Authors:  Hongcang Gu; Christoph Bock; Tarjei S Mikkelsen; Natalie Jäger; Zachary D Smith; Eleni Tomazou; Andreas Gnirke; Eric S Lander; Alexander Meissner
Journal:  Nat Methods       Date:  2010-01-10       Impact factor: 28.547

9.  The role of epigenomics in personalized medicine.

Authors:  Mohamad M Kronfol; Mikhail G Dozmorov; Rong Huang; Patricia W Slattum; Joseph L McClay
Journal:  Expert Rev Precis Med Drug Dev       Date:  2017-01-31

10.  Quantitative comparison of DNA methylation assays for biomarker development and clinical applications.

Authors: 
Journal:  Nat Biotechnol       Date:  2016-06-27       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.